



Humaira Noor

Postdoctoral Scholar, Biomedical Informatics

Bio

BIO

Dr. Humaira Noor is a postdoctoral researcher in the Gevaert Lab with a PhD in glioma genomics from University of New South Wales, Australia. Her expertise spans biomarker discovery, with particular emphasis on prognostic and molecular determinants of glioma treatment-response, radiogenomic model development for early high-risk patient stratification, and the integration of multi-omics and biomedical imaging to advance precision oncology

HONORS AND AWARDS

- Higher Thinking Brain Cancer Fund PhD Scholarship Award, Higher Thinking Brain Cancer Fund, Australia (Apr 2017)
- 1st Prize - 3 Minute Thesis Oral Presentation Competition, Faculty of Medicine, UNSW, Australia (Sept 2020)
- University of New South Wales Postgraduate Completion Scholarship, Faculty of Medicine, UNSW, Australia (Oct 2020)
- EMBL Advanced Training Centre Corporate Partnership Programme fellowship, European Molecular Biology Laboratory (Nov 2020)
- Translational Cancer Research Network (TCRN) Travel Grant, Translational Cancer Research Network, Australia (Sept 2019)
- Prince of Wales Clinical School Travel Grant, UNSW, Australia (Nov 2018)
- Postgraduate Research Support Scheme Travel Grant, UNSW, Australia (Nov 2018)
- GAPSummit Leader of Tomorrow Travel Grant, University of Cambridge (Mar 2016)
- John Morris Industry Research Oral Presentation Award, University of Sydney (Oct 2015)

PROFESSIONAL EDUCATION

- Master of Engineering, Taylor's University (2012)
- Doctor of Philosophy, University Of New South Wales (2022)
- Master of Philosophy, University Of Sydney (2017)
- Master of Engineering, University Of Nottingham (2012)
- PhD, University of New South Wales , Medicine - Neuro-oncology (2022)
- MPhil, University of Sydney , Biomolecular and Chemical Engineering (2017)
- BEng+MEng, University of Nottingham , Chemical Engineering (2012)

STANFORD ADVISORS

- Olivier Gevaert, Postdoctoral Faculty Sponsor

Publications

PUBLICATIONS

- **Response to anti-angiogenic therapy is associated with AIMP protein family expression in glioblastoma and lower-grade gliomas.** *Cancer research communications*
Noor, H., Zheng, Y., Itakura, H., Gevaert, O.
2025
- **A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death.** *NPJ breast cancer*
Noor, H., Zheng, Y., Mantz, A. B., Zhou, R., Kozlov, A., DeMartini, W. B., Chen, S. T., Okamoto, S., Ikeda, D. M., Telli, M. L., Kurian, A. W., Ford, J. M., Vinayak, et al
2025; 11 (1): 79
- **Brain tumor segmentation using deep learning: high performance with minimized MRI data.** *Frontiers in radiology*
Huang, J., Yagmurlu, B., Molleti, P., Lee, R., VanderPloeg, A., Noor, H., Bareja, R., Li, Y., Iv, M., Itakura, H.
2025; 5: 1616293
- **Revealing cancer driver genes through integrative transcriptomic and epigenomic analyses with Moonlight.** *PLoS computational biology*
Nourbakhsh, M., Zheng, Y., Noor, H., Chen, H., Akhuli, S., Tiberti, M., Gevaert, O., Papaleo, E.
2025; 21 (4): e1012999
- **Response to anti-angiogenic therapy is affected by AIMP protein family activity in glioblastoma and lower-grade gliomas.** *bioRxiv : the preprint server for biology*
Noor, H., Zheng, Y., Itakura, H., Gevaert, O.
2025
- **Digital profiling of gene expression from histology images with linearized attention.** *Nature communications*
Pizurica, M., Zheng, Y., Carrillo-Perez, F., Noor, H., Yao, W., Wohlfart, C., Vladimirova, A., Marchal, K., Gevaert, O.
2024; 15 (1): 9886
- **Digital profiling of cancer transcriptomes from histology images with grouped vision attention.** *bioRxiv : the preprint server for biology*
Zheng, Y., Pizurica, M., Carrillo-Perez, F., Noor, H., Yao, W., Wohlfart, C., Marchal, K., Vladimirova, A., Gevaert, O.
2023
- **DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.** *Genomics*
Noor, H., Whittaker, S., McDonald, K. L.
2022; 114 (2): 110289
- **PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma.** *International journal of molecular sciences*
Noor, H., Zaman, A., Teo, C., Sughrue, M. E.
2021; 22 (22)
- **TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.** *Cancers*
Noor, H., Briggs, N. E., McDonald, K. L., Holst, J., Vittorio, O.
2021; 13 (21)